{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:49:47Z","timestamp":1789148987344,"version":"build-2803163510"},"reference-count":15,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lichen amyloidosis (LA) is a predominant type of primary cutaneous amyloidosis that is characterized by persistent and intense skin itching. Although multiple therapeutics strategies are available for its treatment, there is no standard treatment so far. Abrocitinib, an oral small-molecule Janus kinase 1 inhibitor, has been authorized for the treatment of severe atopic dermatitis (AD) and can also provide rapid relief from pruritus. Here, we discuss the case of a 32-year-old man who was diagnosed with LA with severe AD based on the presence of multiple, discrete, and hyperpigmented papules and pruritic, erythematous macules with lichenification of the limbs, trunk, and buttocks. Given the inefficacy of conventional therapy, abrocitinib treatment was recommended in this patient. After 1 month of treatment, the patient\u2019s Eczema Area And Severity Index score decreased significantly from 48 to 15 points, accompanied by a notable reduction in pruritus symptoms. Furthermore, significant improvements were observed in the thickness and pigmentation of the hyperkeratotic papules. Thus, abrocitinib exhibited excellent effectiveness and safety in the treatment of severe AD with LA and warrants further investigation for its potential therapeutic benefits.<\/jats:p>","DOI":"10.3389\/fimmu.2024.1477664","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T06:22:04Z","timestamp":1731565324000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Abrocitinib: a potential therapeutic option for lichen amyloidosis associated with atopic dermatitis"],"prefix":"10.3389","volume":"15","author":[{"given":"Yizhen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00620-9","article-title":"Primary localized cutaneous amyloidosis of keratinocyte origin: an update with emphasis on atypical clinical variants","volume":"22","author":"Hamie","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B2","article-title":"Lichen amyloidosis associated with atopic dermatitis: clinical resolution with cyclosporine","volume":"137","author":"Behr","year":"2001","journal-title":"Arch Dermatol"},{"key":"B3","article-title":"A case of lichen amyloidosus treated with acitretin","volume":"162","author":"Carlesimo","year":"2011","journal-title":"Clin Ter"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15060","article-title":"Lichen amyloidosus as a sweat gland\/duct-related disorder: resolution associated with restoration of sweating disturbance","volume":"176","author":"Shimoda","year":"2017","journal-title":"Br J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01638-3","article-title":"Abrocitinib: first approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2021.2830","article-title":"Feeney C et\u00a0al: Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial","volume":"157","author":"Eichenfield","year":"2021","journal-title":"JAMA Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0278-9","article-title":"Primary localized cutaneous amyloidosis: A systematic treatment review","volume":"18","author":"Weidner","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15005","article-title":"A case of lichen amyloidosis associated with atopic dermatitis successfully treated with dupilumab: A case report and literature review","volume":"34","author":"Aoki","year":"2021","journal-title":"Dermatol Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18756","article-title":"Upadacitinib for treatment- resistant Lichen amyloidosis","volume":"37","author":"Solimani","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15724","article-title":"Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib","volume":"35","author":"Xia","year":"2022","journal-title":"Dermatol Ther"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v11.i11.2549","article-title":"Successful treatment of lichen amyloidosis coexisting with atopic dermatitis by dupilumab: Four case reports","volume":"11","author":"Zhu","year":"2023","journal-title":"World J Clin cases"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.2016.174.issue-6","article-title":"Pathophysiology of pruritus in primary localized cutaneous amyloidosis","volume":"174","author":"Tey","year":"2016","journal-title":"Br J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"Buddenkotte J et\u00a0al: A sensory neuron-expressed IL-31 receptor mediates T helper cell- dependent itch: Involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000519669","article-title":"Influence of janus kinase inhibitors on the neuronal activity as a proof-of-concept model for itch","volume":"35","author":"Wohlrab","year":"2022","journal-title":"Skin Pharmacol Physiol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1477664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T06:22:08Z","timestamp":1731565328000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1477664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":15,"alternative-id":["10.3389\/fimmu.2024.1477664"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1477664","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"article-number":"1477664"}}